Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
Spontaneous reporting of adverse drug reactions (ADRs) remains the cornerstone of postmarketing drug safety surveillance (pharmacovigilance); however, one of its main limitations is incomplete data, thus limiting conclusions about causality assessment.



The primary aim of this study was to assess the completeness of ADR reports sent by general practitioners (GPs) to regional pharmacovigilance centres and the secondary objective was to identify factors associated with complete ADR reports.



All ADR reports sent by GPs to the Midi-Pyrénées Regional Pharmacovigilance Center (Toulouse, France) from 1 January 2010 to 31 December 2013 were reviewed. Healthcare professionals and patients can forward an ADR using either an online form through the Pharmacology Information Bulletin website ( http://www.bip31.fr ) or 'traditional' ADR reports (i.e. email, letter or fax). According to information provided in ADR reports (i.e. patient identification, ADR, date of occurrence, clinical description, drugs, etc.), reports were classified into three groups: 'well-documented', 'slightly documented' or 'poorly documented'. A multivariate logistic regression was performed to investigate potential factors associated with a 'well-documented' ADR report.



During the study period, 613 ADR reports were analysed. Among these reports, only 12.7 % were classified as 'well-documented', 68.5 % as 'slightly documented' and 18.8 % as 'poorly documented'. An association between a 'well-documented' ADR report and its 'seriousness' was found (odds ratio = 1.70 [95 % CI 1.04-2.76], p = 0.01). No association between report completeness ('well-documented' report) and GP practice location or mode of ADR reporting was found.



The study shows that only one out of eight ADR reports from GPs was 'well-documented'. Therefore, it appears to be important to promote further information being available regarding the data required in ADR reports to optimise the evaluation of drug causality.
Service de Pharmacologie Médicale et Clinique, Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de l'Université de Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France. genevieve.durrieu@univ-tlse3.fr.
Geneviève
G
Durrieu
Service de Pharmacologie Médicale et Clinique, Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de l'Université de Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France.
Julien
J
Jacquot
Service de Pharmacologie Médicale et Clinique, Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de l'Université de Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France.
Mathilde
M
Mège
Service de Pharmacologie Médicale et Clinique, Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de l'Université de Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France.
Emmanuelle
E
Bondon-Guitton
Service de Pharmacologie Médicale et Clinique, Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de l'Université de Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France.
Vanessa
V
Rousseau
Service de Pharmacologie Médicale et Clinique, Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de l'Université de Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France.
François
F
Montastruc
Service de Pharmacologie Médicale et Clinique, Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de l'Université de Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France.
Jean-Louis
JL
Montastruc
D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000368:Aged; D000369:Aged, 80 and over; D019985:Benchmarking; D002648:Child; D002675:Child, Preschool; D005260:Female; D005602:France; D058005:General Practitioners; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D060735:Pharmacovigilance; D010818:Practice Patterns, Physicians' / Q000592:standards*; D012044:Regression Analysis; D055815:Young Adult
Therapie. 2014 Sep-Oct;69(5):395-400
25269141
Drug Saf. 2012 Oct 1;35(10):837-44
22924896
Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):565-70; discussion 571-2
22359404
Therapie. 2009 Jul-Aug;64(4):289-94
19804709
Br J Clin Pharmacol. 1996 May;41(5):434-5
8735689
Drug Saf. 2005;28(9):825-33
16119975
Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):808-12
16700082
Therapie. 2017 Jun;72 (3):351-355
27865436
Fundam Clin Pharmacol. 2015 Feb;29(1):106-11
24990220
Drug Saf. 2006;29(5):385-96
16689555
Eur J Clin Pharmacol. 2013 Feb;69(2):237-44
22706618
Drug Saf. 2011 Sep 1;34(9):755-62
21830837
Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):713-8
26861066
Therapie. 2016 Apr;71(2):245-7
27080846
Drug Saf. 2010 May 1;33(5):409-16
20397740
Eur J Clin Pharmacol. 2012 May;68(5):767-75
22116460
Drug Saf. 2014 Jan;37(1):65-77
24343765
BMJ. 2004 Jul 3;329(7456):15-9
15231615
Therapie. 2016 Apr;71(2):143-50
27080832
Lancet. 2000 Oct 7;356(9237):1255-9
11072960